Filing Overview
Registrant: Helix Acquisition Corp., a Cayman Islands special purpose acquisition company, in connection with its proposed business combination with MoonLake Immunotherapeutics AG. The Form 8-K reports an agreement dated February 20, 2022 and was filed February 25, 2022.
Material Transaction and Financing
- Helix, MoonLake, and related parties entered into a Convertible Loan Agreement with Cormorant Private Healthcare Fund IV, L.P. as lender and Biotechnology Value Fund entities as subordinating lenders.
- The lender advanced MoonLake $15.0 million for general corporate purposes, including product and technology development, operations, sales and marketing, management expenses, and salaries.
- The loan is interest-free and unsecured. It matures on the earlier of two business days after the business combination closes or June 30, 2022.
- The loan may not be used to repay any other MoonLake indebtedness.
- Cormorant Fund IV had separately committed to purchase $27.5 million of Helix Class A ordinary shares in a PIPE financing at the business combination closing. Before closing, the lender may assign the loan to Helix in partial satisfaction of that PIPE commitment.
- If the business combination is terminated and the loan remains unpaid, the lender may convert the loan into MoonLake shares upon specified financing or timing events. The conversion price and resulting share count are governed by the loan agreement.
- The loan claims rank senior to MoonLake’s other unsecured subordinated obligations but are subordinated to MoonLake’s current and future creditor claims. Repayment, setoff, novation, and creation of security interests are restricted during the subordination period.
Financial Metrics and Liquidity
This filing does not provide revenue, profit or loss, operating cash flow, margins, total debt, cash balances, or other historical financial statements. It does disclose a $15.0 million interest-free financing facility intended to fund MoonLake until the contemplated transaction closes.
Material Changes and Outlook
The principal reported change is the execution and funding of the Convertible Loan Agreement. The filing does not provide operating guidance, financial forecasts, or updated performance results. Completion of the business combination remains subject to shareholder approval, minimum available closing cash after redemptions, regulatory approvals, and other closing conditions.
Risks, Contingencies, and Unusual Items
- The business combination may be delayed, terminated, or not completed.
- Public shareholder redemptions could prevent satisfaction of the minimum cash condition.
- Cormorant Fund IV is affiliated with Cormorant Asset Management, which is affiliated with certain Helix officers, directors, and the sponsor, creating related-party considerations.
- If the transaction does not close, the loan may remain outstanding until maturity or become convertible into MoonLake equity under specified conditions.
- The filing identifies risks involving regulatory approvals, litigation, Nasdaq listing, transaction disruption, changing industry regulation, transaction costs, competitive conditions, and failure to realize expected benefits.
Important Facts to Verify
- Whether the business combination closed and whether the $15.0 million loan was repaid, rolled over, or converted.
- Whether the $27.5 million PIPE commitment was funded and how the loan affected the purchase commitment.
- The applicable conversion price and potential dilution if the loan converted into MoonLake shares.
- The final shareholder redemption level, available closing cash, regulatory approvals, and other transaction closing conditions.
- The complete terms of the Convertible Loan Agreement filed as Exhibit 10.1.